Crispr Therapeutics AG is trading up 13.2% today at $58.94 following an optimistic presentation by CEO Sam Kulkarni at the Jefferies Global Healthcare Conference.
- Kulkarni highlighted a strong commercial trajectory for its approved therapy, CASGEVY, and provided updates on key pipeline candidates.
- Positive developments were noted for zugo-cel, a CAR-T therapy for autoimmune diseases, which has shown "profound changes" in lupus patients, and CTX310 for cholesterol reduction, with three next-gen assets potentially being Phase III ready by early next year.
- The company also discussed a new, more potent and precise editing platform, suggesting continued innovation beyond its initial successes.